SAUDI ARABIA— Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) has signed a term sheet with Jiangsu Recbio Technology Company Limited for the license, delivery, and transfer of Recombinant Human Papillomavirus (HPV) 9-valent vaccinations.

Once authorized, the listed company will receive exclusive rights to conduct clinical trials and will be in charge of the HPV-9 vaccine’s registration, distribution, and marketing in Saudi Arabia and the MENA region.

According to a market report, the transaction has a one-year lifespan beginning on January 22, 2024, and can be extended with the permission of both sides.

This contract will also include the import of completed and ready-to-fill bulk forms of the vaccine, as well as SPIMACO-supervised local filling and packaging.

It also includes a technology transfer undertaking that will use Recbio’s knowledge, abilities, and expertise to support local HPV-9 vaccine manufacturing.

The strategic alliance seeks to increase vaccination accessibility and cost in the area, guaranteeing safe and timely access for people across the Kingdom and the MENA region.

Jerome Cabannes, CEO of SPIMACO, stated that this partnership with Recbio underscores SPIMACO’s commitment to driving health transformation in Saudi Arabia, marking a critical milestone in the Kingdom’s ambition of becoming a crucial hub for pharmaceutical manufacture.

SPIMACO reported net earnings of SAR 40.40 million (US$10.77 million)  in the first nine months (9M) of 2023, compared to net losses of SAR 67 million (US$ 17.86 million) in 9M-22.

The 9-valent human papillomavirus (HPV) vaccination (9vHPV), often known as Gardasil 9, is a non-infectious second-generation recombinant vaccine.

Gardasil 9 has been approved by the US Food and Drug Administration (FDA) since 2014, making it the only HPV vaccination available in the United States that protects against specific HPV.

It is used in persons aged 9 to 45 to treat and prevent infection with human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58.

HPVs are the leading sexually transmitted viruses, producing precancerous and cancerous lesions.

These cancers include cervical cancer, vulvar and vaginal cancers, anal cancer, some head and neck cancers such as throat and back of mouth cancers, genital warts, and precancerous cervical, vaginal, vulvar, and anal lesions.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.